Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? Journal Article


Authors: Herr, H. W.; Donat, S. M.; Dalbagni, G.
Article Title: Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
Abstract: Purpose: We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer. Materials and Methods: A cohort of 352 patients presenting with T1 bladder cancer on initial transurethral resection was evaluated by second or restaging transurethral resection. All patients received bacillus Calmette-Guerin therapy and 88% were followed for 5 years. Pathological findings on restaging transurethral resection were correlated with tumor features, stage progression frequency and progression-free survival. Results: Of the 352 patients with T1 tumors 203 (58%) had residual tumor on restaging transurethral resection, including 92 (26%) with residual nonmuscle invasive (T1) cancer. During 5 years 66% of cases recurred and 35% progressed in stage. Of the 92 patients with residual T1 cancer 75 (82%) progressed to muscle invasion within 5 years compared to 49 of 260 (19%) who had no or nonT1 tumor detected on restaging transurethral resection. Conclusions: Restaging transurethral resection identifies patients with T1 bladder cancer who are at high risk for early tumor progression, justifying immediate cystectomy. © 2007 American Urological Association.
Keywords: adult; controlled study; aged; aged, 80 and over; middle aged; major clinical study; cancer growth; patient selection; cancer patient; disease free survival; cancer staging; follow up; cancer diagnosis; neoplasm staging; bcg vaccine; cohort analysis; bladder cancer; urinary bladder neoplasms; cancer invasion; minimal residual disease; disease progression; cystectomy; reoperation; bladder neoplasms; transurethral resection; urethra; bladder; bcg vaccination
Journal Title: Journal of Urology
Volume: 177
Issue: 1
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 2007-01-01
Start Page: 75
End Page: 79
Language: English
DOI: 10.1016/j.juro.2006.08.070
PUBMED: 17162005
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 41" - "Export Date: 17 November 2011" - "CODEN: JOURA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Guido Dalbagni
    325 Dalbagni
  2. Sherri M Donat
    174 Donat
  3. Harry W Herr
    594 Herr